Recently, several drugs targeting B cell-associated antigens (e.g., anti-CD20 (rituximab), CD19 (blinatumomab), and CD22 (inotuzumab)), have become available in Europe and USA, thus changing the treatment protocol for B-ALL patients. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.